Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential...

Area of Science:

• Gene Therapy
• Molecular Biology
• Oncology

Background:

• Gene integration into the host genome offers stable therapeutic gene expression but risks oncogene activation or tumor suppressor gene silencing.
• Developing safer gene therapy vectors requires incorporating safety-control elements to mitigate risks associated with non-directional gene integration.

Purpose of the Study:

• To report a novel gene expression cassette for integrating vector systems designed to prevent post-therapeutic tumorigenesis.
• To evaluate the efficacy of a Herpes simplex virus thymidine kinase (hsvTK) gene cassette, driven by the human telomere reverse transcriptase promoter (hTERTp), in selectively targeting tumor cells.

Main Methods:

• Incorporation of the hTERTp-driven hsvTK gene into a self-inactivating HIV-based lentiviral vector.
• Utilizing the hTERT promoter's tumor-specific activity for selective gene expression.
• Administering ganciclovir (GCV) to induce selective deletion of tumorigenic cells expressing hsvTK.

Main Results:

• The hTERTp-hsvTK cassette demonstrated selective differentiation between tumor and normal cells.
• Experimental data confirmed the selective eradication of tumor cells both in vitro and in vivo.
• The system effectively eliminated cancerous cells upon reactivation of the hTERT promoter.

Conclusions:

• The developed hTERTp-hsvTK cassette serves as a potent safety-control element for integrating vector systems.
• This approach significantly enhances the safety profile of gene therapy by enabling selective elimination of potential tumorigenic cells.
• The findings validate the principle of using this element for safer gene delivery strategies in therapeutic applications.